Terms: = Kidney tumors AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
160 results:
1. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
[TBL] [Abstract] [Full Text] [Related]
2. Association between PD-L1 Expression and the prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract] [Full Text] [Related]
3. Machine learning-based integration develops a stress response stated T cell (Tstr)-related score for predicting outcomes in clear cell renal cell carcinoma.
Yang S; Han Z; Tan Z; Wu Z; Ye J; Cai S; Feng Y; He H; Wen B; Zhu X; Ye Y; Huang H; Wang S; Zhong W; Deng Y
Int Immunopharmacol; 2024 May; 132():112017. PubMed ID: 38599101
[TBL] [Abstract] [Full Text] [Related]
4. GHITM regulates malignant phenotype and sensitivity to pd-1 blockade of renal cancer cells via Notch signalling.
Huang S; Liu J; Hu J; Hou Y; Hu M; Zhang B; Luo H; Fu S; Chen Y; Liu X; Chen Z; Wang L
J Cell Mol Med; 2024 Apr; 28(8):e18290. PubMed ID: 38588015
[TBL] [Abstract] [Full Text] [Related]
5. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
[TBL] [Abstract] [Full Text] [Related]
6. Sarcoid-like reaction and hypothyroidism induced by pd-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.
Shrateh ON; Abugharbieh Y; Asbeh YA; Hour H; Awad I; Bannoura S
BMC Pulm Med; 2024 Mar; 24(1):123. PubMed ID: 38459507
[TBL] [Abstract] [Full Text] [Related]
7. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract] [Full Text] [Related]
8. Integrative analysis of LAG3 immune signature and identification of a LAG3-related genes prognostic signature in kidney renal clear cell carcinoma.
Li J; Liu C; Su H; Dong H; Wang Z; Wang Y; Zhao P; Zhang C; Zhao Y; Ma X
Aging (Albany NY); 2024 Jan; 16(3):2161-2180. PubMed ID: 38277212
[TBL] [Abstract] [Full Text] [Related]
9. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract] [Full Text] [Related]
10. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract] [Full Text] [Related]
11. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
12. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract] [Full Text] [Related]
13. prognosis and Clinicopathological Characters of Adult TFEB-Altered Renal Cell Carcinoma: A Single Center Experience of 18 Cases.
Wu J; Cao CZ; Cui HL; Du G; Shi HZ; Liang J; Guo L; Wang YC; Zhang J; Zhou AP; Li CL; Zheng S; Shou JZ
Clin Genitourin Cancer; 2024 Apr; 22(2):261-268.e3. PubMed ID: 38104031
[TBL] [Abstract] [Full Text] [Related]
14. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
15. Knockdown of ADAM8 inhibits the proliferation, migration, invasion, and tumorigenesis of renal clear cell carcinoma cells to enhance the immunotherapy efficacy.
Qu H; Mao M; Wang K; Mu Z; Hu B
Transl Res; 2024 Apr; 266():32-48. PubMed ID: 37992987
[TBL] [Abstract] [Full Text] [Related]
16. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
17. Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma.
Chen J; Chen W; Qu X; Chen Y
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17849-17853. PubMed ID: 37943357
[TBL] [Abstract] [Full Text] [Related]
18. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract] [Full Text] [Related]
20. DNA Methylation Modification Patterns Identify Distinct prognosis and Responses to Immunotherapy and Targeted Therapy in Renal Cell Carcinoma.
Bai D; Cheng Y; Lu X; Namasivayam GP; Sugiyama H
Front Biosci (Landmark Ed); 2023 Sep; 28(9):224. PubMed ID: 37796712
[TBL] [Abstract] [Full Text] [Related]
[Next]
